Faculty
Overview
Registration
View Archive

Accreditation/
Credit Designation

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca and Daiichi Sankyo, Inc.

HER2/3 Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management

HER2/3 Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management


Live, Interactive Webcast
Thursday, September 10, 2020

6:00 PM – 7:00 PM CT

HER2/3 Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management Overview

For over 20 years, trastuzumab has been the foundation of therapy for patients with HER2+ breast cancer, and more recently several novel agents have emerged for continual improvement of treatment outcomes for these patients. HER2 amplification has been increasingly recognized as a frequent abnormality in not only breast cancers, but also gastrointestinal cancers, enabling oncologists to administer HER2/3-targeted therapies to these patients as well. Testing for HER2 is an important step in determining which patients will benefit from treatment with HER2-targeted agents. HER2 amplification and overexpression, however, are much more heterogeneous in gastrointestinal cancers compared with breast cancer, with incomplete membrane staining resulting in the need for an exclusive scoring and interpretation system for gastrointestinal tumor samples. While EGFR, another receptor related to HER2, has long been a target successfully treated in patients with non–small cell lung cancer, novel anti-HER2 agents have emerged to combat tumor resistance. Across tumor types, HER3 amplification may be an indication of treatment resistance, and targeting HER3 in addition to HER2 may be a novel way to specifically treat these tumors.

Benefits of Attending

HER2/3 Across Solid Tumors: Toward Harmonization of Pathology and Oncology to Optimize Diagnosis and Management is a CME-certified live webcast to be held on Thursday, September 10, 2020. This educational activity will provide pathologists with expert perspectives on the rationale for HER2 testing, testing guidelines, and the multidisciplinary diagnosis of HER2/3-positive cancers in the community, with particular focus on role of HER2 testing in breast, lung, and gastrointestinal cancers. The renowned faculty will discuss available evidence to predict and develop future strategies for detection and application of HER2/3 testing in cancer diagnosis and care. The live webcast will feature a multidisciplinary panel of oncology pathologists and one medical oncologist who are familiar with practicing in a collaborative environment to deliver case-based learning. With a look to the future of HER2/3 testing, the expert faculty will discuss next steps needed for accurate identification of patients who would benefit from treatment with HER2/3-targeted therapies.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca and Daiichi Sankyo, Inc.

Learning Objectives

  • Describe diagnostic testing strategies and molecular mechanisms of disease that guide the use of novel and emerging HER2/3-targeted treatment strategies for breast, lung, and gastrointestinal cancers
  • Integrate available data regarding novel HER2/3 treatment paradigms into clinical scenarios for breast, lung, and gastrointestinal cancers
  • Apply multidisciplinary approaches that ensure diagnostic information related to HER2/3 are utilized at key clinical decision points along the cancer disease continuum

Target Audience

This educational program is directed toward the ASCP audience of oncology pathologists. Other health care professionals involved in the diagnosis and treatment of cancer will also be invited to participate.

Disclaimer

This satellite symposium is independent and not part of the official American Society for Clinical Pathology 2020 accredited continuing medical education (CME) virtual annual meeting education program.

Program Chair

Lynette M. Sholl, MD
Lynette M. Sholl, MD
Associate Professor, Pathology
Harvard Medical School
Associate Pathologist, Pathology
Brigham and Women’s Hospital
Boston, MA

Faculty

Pasi A. Jänne, MD, PhD
Pasi A. Jänne, MD, PhD
Director, Lowe Center for Thoracic Oncology
Professor of Medicine, Harvard Medical School
Director, Belfer Center for Applied Cancer Science
Dana Farber Cancer Institute
Boston, MA

Tiffany A. Traina, MD
Tiffany A. Traina, MD
Associate Professor of Medicine
Weill Cornell Medicine
Associate Attending Physician
Vice Chair, Oncology
Department of Medicine
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
New York, NY

Jonathan A. Nowak, MD, PhD
Jonathan A. Nowak, MD, PhD
Assistant Professor of Pathology
Brigham and Women’s Hospital
Boston, MA

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.




Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By